01
Actor registration
Economic-operator registration and SRN logic.
EUD–03 · EUDAMED question analysis
EUDAMED and Combination Products: questions hidden between drug, device and data.
Combination products are expensive because the decisive questions rarely stay inside one discipline. EUDAMED adds a further layer: structured visibility around actors, devices, certificates and market surveillance.
FILE 01 · Regulatory trigger
What changes on 28 May 2026.
The European Commission states that the first four EUDAMED modules become mandatory from 28 May 2026: Actor registration, UDI/Devices registration, Notified Bodies and Certificates, and Market Surveillance.
The strategic relevance is not limited to registration. Once actors, devices, certificates and market-surveillance activity move into a more structured European information environment, R&D, regulatory, quality and commercial teams need better questions than a checklist normally provides.
02
UDI/Devices
Device data, Basic UDI-DI and registration visibility.
03
NBs & Certificates
Notified-body and certificate information.
04
Market Surveillance
Regulatory visibility beyond initial registration.
Official source basis: European Commission EUDAMED overview and module pages, including the notice that the first four modules become mandatory from 28 May 2026. See European Commission EUDAMED overview, mandatory use notice, Actor module, and UDI/Devices module.
FILE 02 · Boundary complexity
Combination products make the known frame unstable.
A combination product can carry a pharmaceutical logic, a device logic, a usability logic, a data logic, a supply-chain logic and a certification logic at the same time.
That is exactly the condition in which standard checklists become insufficient. The expensive question is often not hidden in one regulation. It is hidden in the interaction between disciplines, records, claims, design choices, partners and future visibility.
FILE 03 · Visibility layer
EUDAMED may change what the market can infer.
Once product, actor, device and certificate information becomes more structured, the surface available for inference changes.
Competitors may not need secret information to read category movement. They may read timing, absence, classification, dependencies, certificate patterns and surveillance themes. The Non-Consensus work is to ask which of those patterns matter before they become obvious.
FILE 04 · Question economics
The value is not in more documentation. It is in better pre-document questions.
The nescimus deliverable does not replace your regulatory, legal or quality work. It sharpens what should be asked before those workstreams lock into execution.
For combination products, a single well-derived question can redirect experiments, supplier decisions, documentation logic, claim strategy or competitive positioning. That is why the first deliverable is deliberately compact: 10 pages, 10–15 questions, derivation and prioritisation.
FILE 05 · Non-Consensus questions
Questions that may deserve escalation before execution starts.
- Which element of the product currently dominates the internal framing: drug, device, data, usability, certification or surveillance?
- Which component would competitors use to infer our strategic direction once EUDAMED records become more structured?
- Which Basic UDI-DI or device-registration assumptions may reveal more than the team intends?
- Which certificate dependencies could become a visible constraint on development timing?
- Which claim boundary is being handled as wording when it is actually a product-strategy question?
- Which surveillance theme could affect R&D direction before it appears as a commercial issue?
- Which partner dependency becomes more visible because the EUDAMED information environment is changing?
- Which combination-product option becomes commercially attractive because competitors will avoid the boundary?
- Which option becomes less attractive because the boundary creates future comparability or delay?
- Which internal expert knows part of the answer but not the whole question?
- Which classification question should be formulated before a submission or registration path becomes politically difficult to change?
- Which non-obvious experiment would reduce uncertainty before regulatory execution begins?
FILE 06 · Buying triggers
When the €1,970 analysis makes commercial sense.
Drug-device ambiguity
The product sits near a boundary where one vocabulary is not enough.
Certificate dependencies matter
Development timing may depend on notified-body, certificate or device-registration logic.
Market inference is possible
Structured data may allow competitors or partners to read strategy from administrative records.
A decision is premature
The team is about to execute a path before the hidden questions have been formulated.
This analysis does not constitute legal, regulatory or notified-body advice. It is a structured question analysis for R&D, strategy, product and regulatory-facing teams.
Single fixed fee
€1,970net · plus VAT where applicable
A document that can pay for itself with one redirected research direction.
- Immediate Stripe checkout
- 10-page structured PDF deliverable
- 10–15 Non-Consensus questions, derived & classified
- Clustering by technical and economic leverage
- Prioritisation by differentiation potential
- Zoom briefing & one revision round
FILE 08 · FAQ
Before you commission the EUDAMED analysis.
Q.01Is this a regulatory classification opinion?+
No. It is not legal, regulatory or notified-body advice. It is a question analysis that can help internal teams identify what to escalate.
Q.02Why focus on combination products?+
Combination products concentrate high-cost uncertainty because drug, device, data, quality and market logics interact.
Q.03Why does EUDAMED matter here?+
EUDAMED increases structured visibility around medical-device actors, device data, certificates and surveillance, which can affect how boundary products are interpreted.
Q.04What does the report include?+
A compact 10-page analysis with 10 to 15 derived questions, technical or strategic classification, clustering and prioritisation.
Q.05How does this support internal teams?+
It gives R&D, Regulatory, Quality, Legal and Strategy a sharper question set before execution absorbs attention.
Pay now. The questions take it from there.
Immediate Stripe checkout for the fixed-fee analysis. After payment, the Zoom briefing defines the dimension set. Delivery follows within 3–5 business days from the Zoom briefing.